HBV

World Hepatitis Alliance raise awareness of viral hepatitis on World Hepatitis Day as research shows hepatitis B and C cause significantly higher cancer risk than smoking a daily pack of cigarettes

Retrieved on: 
Thursday, July 27, 2023
World Hepatitis Alliance, WHA, EASL, Hepatitis, Life, HIV, Infection, World Hepatitis Day, Cancer, Hepatitis B, WHD, Liver cancer, CDA, Epidemic, C3, Death, Patient, Tuberculosis, Risk, Viral, Mortality, Viral hepatitis, Virus, HBV, HCV, Malaria, Vaccine

LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.

Key Points: 
  • LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.
  • The report finds that hepatitis B and C infected individuals "have a similar or significantly higher risk of developing cancer than someone who actively smokes one pack of cigarettes per day."
  • It concludes that HBV and HCV should be "considered as cancer causing infections and international guidelines should be reconsidered accordingly."
  • A recent survey2 from WHA found that nearly half (42%) of people globally are unaware that one of the leading causes of liver cancer is viral hepatitis.

World Hepatitis Alliance raise awareness of viral hepatitis on World Hepatitis Day as research shows hepatitis B and C cause significantly higher cancer risk than smoking a daily pack of cigarettes

Retrieved on: 
Thursday, July 27, 2023
World Hepatitis Alliance, WHA, EASL, Hepatitis, Life, HIV, Infection, World Hepatitis Day, Cancer, Hepatitis B, WHD, Liver cancer, CDA, Epidemic, C3, Death, Patient, Tuberculosis, Risk, Viral, Mortality, Viral hepatitis, Virus, HBV, HCV, Malaria, Vaccine

LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.

Key Points: 
  • LONDON, July 27, 2023 /PRNewswire/ -- Today, World Hepatitis Day (WHD) launches with the call to action 'We're not waiting'.
  • The report finds that hepatitis B and C infected individuals "have a similar or significantly higher risk of developing cancer than someone who actively smokes one pack of cigarettes per day."
  • It concludes that HBV and HCV should be "considered as cancer causing infections and international guidelines should be reconsidered accordingly."
  • A recent survey2 from WHA found that nearly half (42%) of people globally are unaware that one of the leading causes of liver cancer is viral hepatitis.

New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Retrieved on: 
Monday, July 24, 2023
AIDS, Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Science, International, HIV, Pharmacokinetics, Tablet, Coinfection, Pregnancy, IAS, HBV, Conference, Safety, Pharmaceutical industry, Vaccine

The data were presented at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS 2023), taking place July 23-26 in Brisbane, Australia.

Key Points: 
  • The data were presented at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS 2023), taking place July 23-26 in Brisbane, Australia.
  • No adverse events (AEs) leading to premature discontinuation and no drug-related AEs were observed in the pregnant women or neonates.
  • “The clinical profile of Biktarvy is further supported by safety data and no mother-to-child transmission in this study and data showing that normal dosing may be appropriate.
  • Indications and Important Safety Information, including Boxed Warning on post treatment acute exacerbation of hepatitis B, for Biktarvy.

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

Retrieved on: 
Thursday, July 20, 2023
Lymphoma, Infection, Insulin resistance, Gilead Sciences, Medicaid, Medical Affairs Bureau, Depression, Partnership, Office of Inspector General, U.S. Department of Health and Human Services, Diabetes, HIV, Vaccination, Arthritis, Liver disease, Human services, Public, COVID-19, Cancer, Deficit spending, Quality of life, Hepatitis B virus, Research, Medicine, Kidney, Gilead, Liver cancer, CDC, Organization, CDA, Patient, Risk, Fibromyalgia, U.S. CDC, WHO, Liver failure, Viral hepatitis, Cirrhosis, HBV, HCV, Virus, World Health Organization, Fatigue, Pharmaceutical industry, Vaccine, Medicare, Granblue Fantasy: Relink

LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.

Key Points: 
  • LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.
  • CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.
  • Both viruses are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.
  • The Relink grant program aims to identify and work to bridge the gaps that remain in linking patients back to necessary care and treatment.

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

Retrieved on: 
Thursday, July 20, 2023
Health, Foundation, Philanthropy, Managed Care, Oncology, Lymphoma, Infection, Insulin resistance, Gilead Sciences, Medicaid, Medical Affairs Bureau, Depression, Partnership, Office of Inspector General, U.S. Department of Health and Human Services, Diabetes, HIV, Vaccination, Arthritis, Liver disease, Human services, Public, COVID-19, Cancer, Deficit spending, Quality of life, Hepatitis B virus, Research, Medicine, Kidney, Gilead, Liver cancer, CDC, Organization, CDA, Patient, Risk, Fibromyalgia, U.S. CDC, WHO, Liver failure, Viral hepatitis, Cirrhosis, Virus, HBV, HCV, World Health Organization, Fatigue, Pharmaceutical industry, Vaccine, Medicare

The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.

Key Points: 
  • The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program.
  • CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care.
  • Both viruses are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.
  • The relink grant program aims to identify and work to bridge the gaps that remain in linking patients back to necessary care and treatment.

Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.

Retrieved on: 
Thursday, July 20, 2023
Philanthropy, Health, Infectious Diseases, Hospitals, Foundation, Pharmaceutical, Biotechnology, Infection, Gilead Sciences, Medical Affairs Bureau, U.S. Department of Defense Strategy for Operating in Cyberspace, Vaccination, Liver disease, Human services, Office of Inspector General, U.S. Department of Health and Human Services, Hepatitis B virus, Liver cancer, Organization, Risk, Science, WHO, Liver failure, Viral hepatitis, Cirrhosis, HBV, HCV, World Health Organization, Disease, Pharmaceutical industry, Vaccine

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care.
  • Both HCV and HBV are responsible for increasing rates of cirrhosis, liver cancer, liver failure and premature deaths.
  • Recognizing the growing risk of viral hepatitis, the World Health Organization (WHO) has set a global target to eliminate it as a public health threat by 2030.
  • “Gilead has been committed to improving the lives of people living with liver disease for more than two decades, and we are thrilled to expand our support to healthcare organizations through the new Gilead Relink grant program,” said Macky Natha, Vice President, Medical Affairs, Gilead Sciences.

Velia Therapeutics Announces Appointment of Veteran Drug Developer, John McHutchison, AO, MD as President and Chief Executive Officer

Retrieved on: 
Wednesday, July 19, 2023
Gilead Sciences, Therapy, AO, CSO, New Drug Application, Biotechnology, Foresite Capital, Proteome, Research, Doctor of Philosophy, Science, MD, Patient, SAN, Column, Shirin David, HBV, HCV, Management, Pharmaceutical industry

Dr. McHutchison is the former CEO and President at Assembly Biosciences, and a noted biotech industry leader with extensive executive experience.

Key Points: 
  • Dr. McHutchison is the former CEO and President at Assembly Biosciences, and a noted biotech industry leader with extensive executive experience.
  • He joins Shelly Meeusen, PhD, Chief Scientific Officer and Velia's scientific co-founders; Eric Olson, PhD, Alan Saghatelian, PhD, Richard Scheller, PhD and Jonathan Weissman, PhD.
  • a biotechnology company pioneering the therapeutic potential within the dark matter of the human proteome, backed by The Column Group and Foresite Capital, today announced the appointment of industry leader John McHutchison, AO, MD as President and Chief Executive Officer.
  • Millie Ray, PhD, Board Director at Velia, added, "We are extremely fortunate to have John join us at Velia.

VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Retrieved on: 
Wednesday, July 19, 2023
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, Other Health, Health, Science, Oncology, Infection, Hepatitis B vaccine, Partnership, Marketing, Hepatitis B, Hepatitis B virus, VBI, Hepatitis D, Immunization, Vaccine, HBV, Disease, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)] is now available in the Netherlands and Belgium for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults.
  • It can be expected that hepatitis D will also be prevented by immunization with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
  • As part of the marketing and distribution partnership announced in September 2022, PreHevbri will be available in the Netherlands and Belgium through Valneva’s existing commercial infrastructure and distribution networks.
  • Jeff Baxter, President and CEO of VBI, commented: “We are excited to announce the launch of PreHevbri in the Netherlands and Belgium through our partnership with Valneva.

Japan In-Vitro Diagnostics (IVD) Market Analysis Report 2023-2028: Major Deals, Trends and Recent Developments - Roche Diagnostics is the Leader, Followed by Sysmex - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 18, 2023
Health, Infectious Diseases, Other Health, Research, Science, Biotechnology, Laboratory, HIV, Hematology, TB, Abbott, Abbott Laboratories, Segment, Infection, Cancer, Genetic testing, Nanopore sequencing, Danaher Corporation, Aline Betancourt, Thermo Fisher Scientific, BioMérieux, Roche, Growth, IVD, SA, HBV, HCV, Conditional sentence, Sysmex Corporation, Medical device, Pharmaceutical industry, Fine chemical

The "Japan In-Vitro Diagnostics (IVD) Market (By Segment and Company), Size, Share, Major Deals, Trends and Recent Developments - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Japan In-Vitro Diagnostics (IVD) Market (By Segment and Company), Size, Share, Major Deals, Trends and Recent Developments - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Japan is facing the challenges of fighting with infectious disease including HBV, TB, HCV, and HIV, as well as various chronic disease and cancer.
  • In the Japan IVD market, Roche Diagnostics is the leader, followed by Sysmex Corporation.
  • Abbott Laboratories, Thermo Fisher Scientific Inc., and Danaher Corporation are the other top three players in the Japan IVD market.

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
Intercept, Bachelor, Drug development, Therapy, Senior, Pharmacia, Virology, Biotechnology, ATCC, Viral, Pharmacia & Upjohn, ATCC (company), Doctor of Philosophy, Chemistry, Development, HBV, Management, Arbutus

“We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.

Key Points: 
  • “We are excited to welcome Dr. Rewolinski to the Arbutus Board,” said William Collier, President and Chief Executive Officer of Arbutus.
  • She currently serves as a board member for Lannett Company, Inc., and American Type Culture Collection (ATCC).
  • Dr. Rewolinski, commented, “This is an exciting time to join the Board of Arbutus.
  • I look forward to working with my fellow Board members to support Arbutus in its continued efforts to develop treatments for HBV and coronaviruses.”